American College of Cardiology

Among patients with severe aortic stenosis, the ACURATE IDE trial failed to demonstrate that Acurate neo2 valve was noninferior to a commercially available valve. Mortality, stroke, and rehospitalization tended to be higher in the Acurate neo2 group vs. the conventional TAVR group. Get the details: https://bit.ly/3AjwYGR #TCT2024

A QFR-guided revascularization strategy did not provide the same prognostic benefits as an FFR-guided strategy for patients with intermediate coronary stenosis, based on findings from the FAVOR III Europe trial presented at #TCT2024. Get the details: https://bit.ly/3YIXYZF #ACCIC

ACC is on the lookout for a board-certified Nurse Practitioner (NP) or Physician Assistant (PA) to step into the role of Vice Chair for the Certified Cardiovascular Knowledge (CCK) Exam for NPs and PAs. This is a fantastic chance for an innovative leader in cardiovascular team-based care and education to make a significant impact! After a two-year term as Vice Chair, you’ll transition to Chair for an additional two years, shaping the future of cardiovascular education for NPs and PAs. If you are an innovative and collaborative team member specializing in General Cardiology in the outpatient setting with 50% of your time spent in direct patient care, we want to hear from you! 🗓️ Application Deadline: Thursday, Oct. 31 Learn more and apply at https://bit.ly/47GxtqI Let’s elevate cardiovascular care together! . . . #Cardiology #NursePractitioner #PhysicianAssistant #ACCLeadership #ACCEd

Both acute and long-term colchicine use to treat patients with acute myocardial infarction (MI) did not reduce cardiovascular death, MI, stroke or ischemia-driven revascularization, based on findings from the CLEAR SYNERGY trial presented during #TCT2024. Read more: https://bit.ly/3Yp52JF

Findings from the ECLIPSE trial show routine use of orbital atherectomy did not improve minimal stent area or reduce target vessel failure at 1 year compared with conventional balloon angioplasty prior to implantation of a drug-eluting stent in severely calcified coronary lesions. Read more: https://bit.ly/3A8Tnqq #TCT2024 #ACCIC

📢 ACC is accepting applications for the next #CardioSmart Editor. The new editor's term will be for three years beginning May 2025. Candidates should understand how patients and consumers learn and apply medical information and should have experience with implementation and dissemination of clinical content. Applications due Friday, Nov. 1. ➡️ https://bit.ly/3BSgENC

Findings from TAVR UNLOAD show preemptive #TAVR to be safe, but not superior to CASS in patients with #HFrEF and moderate AS. While underpowered, researchers did note potential benefits to quality of life with preemptive TAVR in select symptomatic patients. https://bit.ly/3YmChNQ #JACC #TCT2024 #HeartFailure

Results from EARLY TAVR and EVOLVED late-breaking trials presented at #TCT2024 explore whether early aortic valve intervention improves outcomes in patients with asymptomatic aortic stenosis. Catch the highlights here: https://bit.ly/3AshgZX #TAVR #ACCIC

🌍 Connect with peers and learn from experts at #ACC25! Join us in Chicago, March 29 – 31, 2025. Early bird registration is now open! Learn more and register today: https://bit.ly/4hlPWgD

In this month's #CardiologyMag article, explore the numerous ways that cardiac electrophysiologists and cardiothoracic surgeons can improve patient-focused care and outcomes by collaborating and enhancing each other's practice. Read more: 🔗 https://bit.ly/3YkgdDs